Showing 761-770 of 1116 results for "".
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Johnson & Johnson Vision Appoints Rajesh K. Rajpal, MD, Chief Medical Officerhttps://modernod.com/news/johnson-johnson-vision-appoints-rajesh-k-rajpal-md-chief-medical-officer/2477634/Johnson & Johnson Vision has appointed Rajesh K. Rajpal, MD, as Chief Medical Officer and Global Head of Clinical and Medical Affairs. In this role, Dr. Rajpal will lead the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of pa
- Iveric Bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officerhttps://modernod.com/news/iveric-bio-appoints-pravin-u-dugel-md-as-executive-vice-president-and-chief-strategy-and-business-officer/2477448/Iveric bio announced the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer, effective April 1, 2020. In this role, Dr. Dugel will help shape Iveric bio’s business development strategy going forward. Dr. Dugel brings more than 25 years’ experie
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- Nick Mamalis, MD, Named 2019 ASCRS President as ASCRS Unveils New Brandinghttps://modernod.com/news/nick-mamalis-md-named-2019-ascrs-president-as-ascrs-unveils-new-branding/2476560/Nick Mamalis, MD, a well-known ophthalmologist and longtime co-editor of the Journal of Cataract & Refractive Surgery, assumed his role as president of the American Society of Cataract and Refractive Surgery (ASCRS) during the ASCRS meeting’s opening general session here this p
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- First Implantation of RayOne Aspheric Fully Preloaded IOL in US Completed by William F. Wiley, MDhttps://modernod.com/news/first-implantation-of-rayone-aspheric-fully-preloaded-iol-in-us-completed-by-william-f-wiley-md/2476324/The first US implantation of Rayner’s flagship RayOne Aspheric fully preloaded monofocal IOL (RAO600C) was successfully performed by William F. Wiley, MD, at the Brecksville Surgery Center in Cleveland, Ohio, following FDA approval in late 2018. After the surgery, Dr. Wiley commented that
- Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/Azura Ophthalmics announced positive topline efficacy and safety results from a phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD). The trial met its prim
- RetinAI and FVS Announce CE-MDR Certification for Co-Developed AI-Based DR Screening Algorithm, LuxIAhttps://modernod.com/news/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-dr-screening-algorithm-luxia/2482773/RetinAI US and Fundación Ver Salud (FVS) have jointly announced that LuxIA, their co-developed AI algorithm for diabetic retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n